ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Inclusion Criteria:

Histologically or cytologically confirmed diagnosis of adenocarcinoma of the colon or rectum, metastatic disease
Wild-type KRAS tumor status
Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2
Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease
Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC)
Adequate hematologic, renal, hepatic and metabolic function

Exclusion Criteria:

Symptomatic brain metastases requiring treatment
Prior anti-epidermal growth factor receptor (EGFr) antibody therapy (eg, panitumumab or cetuximab) or treatment with small molecule EGFr inhibitors (eg, gefitinib, erlotinib, lapatinib)
Antitumor therapy (eg, chemotherapy, hormonal therapy, immunotherapy, antibody therapy, radiotherapy), or investigational agent or therapy ≤ 30 days before randomization.
Clinically significant cardiovascular disease
Active infection requiring systemic treatment or any uncontrolled infection ≤14 days prior to randomization